Recent studies provide additional support for the role of complement activation in MS, identifying elevated levels of activation products (e.g. C3a, C4a, Ba and Bb) in the cerebrospinal fluid (CSF) of patients with MS. Here, C3 is linked to myeloid sarcoma.